Cel
The emergence of Antibiotic-resistant bacteria (ARB) is a global problem, having recently been elevated to the top three threats identified by the World Health Organisation (WHO), and subject of numerous national and international government activities, including the Trans-Atlantic Task Force on Antimicrobial Resistance established by the US and EU presidencies. The estimated costs of ARB are around € 1.5 Billion per year in Europe, with an estimated 25,000 deaths (European Center for Disease prevention and Control/European Medicines Agency “time to react”). While the threat of antimicrobial resistance is growing, so are the challenges to bringing forward new therapeutic options for patients infected with resistant organisms. There is a need for a better understanding of how antimicrobial resistance is evolving globally, of what novel molecular mechanisms can be exploited as new forms of antimicrobial therapy and of how to more efficiently develop new treatments so they can be more rapidly brought to patients in need.
The over-arching concept of New Drugs for Bad Bugs (ND4BB) is to create an innovative public-private collaborative partnership that will positively impact all aspects of ARB through the discovery and development of novel agents for the treatment, prevention and management of patients with bacterial infections. COMBACTE is one of the first projects to be launched under this programme with the aim of developing a broad European network of fully capable and Good Clinical Practice (GCP) compliant clinical investigation sites to execute clinical trials enabling the registration of novel agents to be used in the treatment of patients with bacterial infections. The growth and application of the network will be supported with robust microbiologic surveillance data and clinical epidemiologic data. To reduce the time and or cost of clinical development, novel clinical trial designs will be outlined and supported through analysis of publically available and consortium-shared non-clinical and clinical data. In addition to executing the initial set of clinical trials, investigations of patient and pathogen-related biomarkers and the logistical and decision making impact of rapid diagnostics will be conducted.
Dziedzina nauki
Zaproszenie do składania wniosków
IMI-JU-06-2012
Zobacz inne projekty w ramach tego zaproszenia
System finansowania
JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)Koordynator
151 85 Sodertaelje
Szwecja
Zobacz na mapie
Uczestnicy (38)
3584 CX Utrecht
Zobacz na mapie
1200 Bruxelles / Brussel
Zobacz na mapie
50937 Koeln
Zobacz na mapie
87000 Limoges
Zobacz na mapie
08036 Barcelona
Zobacz na mapie
Zakończenie uczestnictwa
25030 BESANCON CEDEX
Zobacz na mapie
38124 Braunschweig
Zobacz na mapie
75654 Paris
Zobacz na mapie
2000 Antwerpen
Zobacz na mapie
1211 Geneve
Zobacz na mapie
3703 CD Zeist
Zobacz na mapie
79106 Freiburg
Zobacz na mapie
Zakończenie uczestnictwa
1011 Lausanne
Zobacz na mapie
Zakończenie uczestnictwa
6525 XZ Nijmegen
Zobacz na mapie
BS10 5NB Bristol
Zobacz na mapie
Zakończenie uczestnictwa
38041 GRENOBLE
Zobacz na mapie
WC1A 1DG LONDON
Zobacz na mapie
2340 Beerse
Zobacz na mapie
41071 Sevilla
Zobacz na mapie
97159 Pointe-à-Pitre Pointe-à-Pitre
Zobacz na mapie
581 83 Linkoping
Zobacz na mapie
10561 Athina
Zobacz na mapie
72074 Tuebingen
Zobacz na mapie
17489 Greifswald
Zobacz na mapie
69622 Villeurbanne Cedex
Zobacz na mapie
3015 GD Rotterdam
Zobacz na mapie
08036 Barcelona
Zobacz na mapie
28046 MADRID
Zobacz na mapie
64239 Tel Aviv
Zobacz na mapie
1649-016 Lisboa
Zobacz na mapie
7270 Davos
Zobacz na mapie
20122 Milano
Zobacz na mapie
75014 Paris
Zobacz na mapie
8006 Zurich
Zobacz na mapie
75011 PARIS
Zobacz na mapie
07054 Parsippany
Zobacz na mapie
CT13 9NJ Sandwich
Zobacz na mapie
1050 Bruxelles / Brussel
Zobacz na mapie